High levels of C-reactive protein are associated with reduced vagal modulation and low physical activity in young adults

Scandinavian Journal of Medicine and Science in Sports

Volumn 22, Issue 2, 2012, Pages 278-284

  Soares Miranda, L ^a,b   Negrao, C E ^b   Antunes Correa, L M ^b   Nobre, T S ^b   Silva, P ^a   Santos, R ^a   Vale, S ^a   Mota, J ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Accelerometer; Heart rate variability; Inflammation; Physical activity; Young adults

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; FEMALE; HEART RATE; HUMAN; MALE; MOTOR ACTIVITY; PHYSIOLOGY; VAGUS NERVE;

AUTONOMIC NERVOUS SYSTEM; C-REACTIVE PROTEIN; FEMALE; HEART RATE; HUMANS; MALE; MOTOR ACTIVITY; VAGUS NERVE; YOUNG ADULT;

EID: 84858200145     PISSN: 09057188     EISSN: 16000838     Source Type: Journal    
DOI: 10.1111/j.1600-0838.2010.01163.x     Document Type: Article

References (43)

1. Allison MA, Pavlinac P, Wright CM. The differential associations between HDL, non-HDL and total cholesterols and atherosclerotic calcium deposits in multiple vascular beds. Atherosclerosis 2007: 194: e87-e94.
2. Araujo F, Antelmi I, Pereira AC, Latorre Mdo R, Grupi CJ, Krieger JE, Mansur AJ. Lower heart rate variability is associated with higher serum high-sensitivity C-reactive protein concentration in healthy individuals aged 46 years or more. Int J Cardiol 2006: 107: 333-337.
3. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H, Sudan S, Czura CJ, Ivanova SM, Tracey KJ. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002: 195: 781-788.
4. Biro G, Hulshof KF, Ovesen L, Amorim Cruz JA. Selection of methodology to assess food intake. Eur J Clin Nutr 2002: 56(Suppl. 2): S25-S32.
5. Brage S, Wedderkopp N, Franks PW, Andersen LB, Froberg K. Reexamination of validity and reliability of the CSA monitor in walking and running. Med Sci Sports Exerc 2003: 35: 1447-1454.
6. Braun C, Kowallik P, Freking A, Hadeler D, Kniffki KD, Meesmann M. Demonstration of nonlinear components in heart rate variability of healthy persons. Am J Physiol 1998: 275: H1577-H1584.
7. Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, Haaksma J, Dijk WA, Visser KR, Boomsma F, Dunselman PH. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine multicenter trial study group. J Am Coll Cardiol 1996: 28: 1183-1189.
8. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004: 350: 1387-1397.
9. Esliger DCJL, Barnes JD, Tremblay MS. Standardizing and optimizing the use of accelerometer data for free-living physical activity monitoring. J Phy Activity Health 2005: 3: 366-383.
10. Freedson PS, Melanson E, Sirard J. Calibration of the computer science and applications, Inc accelerometer. Med Sci Sports Exerc 1998: 30: 777-781.
11. Gilder M, Ramsbottom R. Measures of cardiac autonomic control in women with differing volumes of physical activity. J Sports Sci 2008: 26: 781-786.
12. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen L, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgozoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth joint task force of the European society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007: 14(Suppl. 2): S1-S113.
13. Jae SY, Heffernan KS, Yoon ES, Lee MK, Fernhall B, Park WH. The inverse association between cardiorespiratory fitness and C-reactive protein is mediated by autonomic function: a possible role of the cholinergic antiinflammatory pathway. Mol Med 2009: 15: 291-296.
14. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB.C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999: 99: 237-242.
15. La Rovere MT, Pinna GD, Maestri R, Mortara A, Capomolla S, Febo O, Ferrari R, Franchini M, Gnemmi M, Opasich C, Riccardi PG, Traversi E, Cobelli F. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003: 107: 565-570.
16. Lampert R, Bremner JD, Su S, Miller A, Lee F, Cheema F, Goldberg J, Vaccarino V. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am Heart J 2008: 156: e751-e757.
17. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006: 83: 456S-460S.
18. Madsen T, Christensen JH, Toft E, Schmidt EB.C-reactive protein is associated with heart rate variability. Ann Noninvasive Electrocardiol 2007: 12: 216-222.
19. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004: 43: 1056-1061.
20. Mourot L, Bouhaddi M, Perrey S, Cappelle S, Henriet MT, Wolf JP, Rouillon JD, Regnard J. Decrease in heart rate variability with overtraining: assessment by the Poincare plot analysis. Clin Physiol Funct Imaging 2004: 24: 10-18.
21. Nunan D, Donovan G, Jakovljevic DG, Hodges LD, Sandercock GR, Brodie DA. Validity and reliability of short-term heart-rate variability from the Polar S810. Med Sci Sports Exerc 2009: 41: 243-250.
22. Panagiotakos DB, Pitsavos C, Chrysohoou C, Kavouras S, Stefanadis C. The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA study. Prev Med 2005: 40: 432-437.
23. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000: 102: 2165-2168.
24. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon ROIII, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SCJr., Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation 2003: 107: 499-511.
25. Radespiel-Troger M, Rauh R, Mahlke C, Gottschalk T, Muck-Weymann M. Agreement of two different methods for measurement of heart rate variability. Clin Auton Res 2003: 13: 99-102.
26. Rennie KL, Hemingway H, Kumari M, Brunner E, Malik M, Marmot M. Effects of moderate and vigorous physical activity on heart rate variability in a British study of civil servants. Am J Epidemiol 2003: 158: 135-143.
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997: 336: 973-979.
28. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001: 285: 2481-2485.
29. Rothney MP, Schaefer EV, Neumann MM, Choi L, Chen KY. Validity of physical activity intensity predictions by ActiGraph, Actical, and RT3 accelerometers. Obesity (Silver Spring) 2008: 16: 1946-1952.
30. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Abedini S, Hansen JF. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004: 25: 363-370.
31. Shemesh T, Rowley KG, Shephard M, Piers LS, O'Dea K. Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+and Cholestech LDX point-of-care methods in remote Australian Aboriginal communities. Clin Chim Acta 2006: 367: 69-76.
32. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 2007: 13: 178-184.
33. Soares-Miranda L, Sandercock G, Valente H, Vale S, Santos R, Mota J. Vigorous physical activity and vagal modulation in young adults. Eur J Cardiovasc Prev Rehabil 2009: 16: 705-711.
34. Stein PK, Barzilay JI, Chaves PH, Traber J, Domitrovich PP, Heckbert SR, Gottdiener JS. Higher levels of inflammation factors and greater insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older individuals: the cardiovascular health study. J Am Geriatr Soc 2008: 56: 315-321.
35. Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, Timmerman KL, McFarlin BK, Coen PM, Talbert E. The influence of exercise training on inflammatory cytokines and C-reactive protein. Med Sci Sports Exerc 2007: 39: 1714-1719.
36. Task F. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996: 93: 1043-1065.
37. Thayer JF, Fischer JE. Heart rate variability, overnight urinary norepinephrine and C-reactive protein: evidence for the cholinergic anti-inflammatory pathway in healthy human adults. J Intern Med 2009: 265: 439-447.
38. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007: 117: 289-296.
39. Tsuji H, Venditti FJJr, Manders ES, Evans JC, Larson MG, Feldman CL, Levy D. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994: 90: 878-883.
40. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 2005: 4: 673-684.
41. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004: 25: 1197-1207.
42. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003: 421: 384-388.
43. Zwaka TP, Hombach V, Torzewski J.C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001: 103: 1194-1197.